Sarepta Therapeutics cuts ribbon on new headquarters
Sarepta Therapeutics executives and employees joined local, state and federal officials, members of the Massachusetts life science and biotech community and representatives from Duchenne muscular dystrophy (DMD) patient advocacy groups at a ribbon-cutting ceremony at the new location.
The company began relocating its headquarters in early 2013 and has since expanded to employ more than 150 people, approximately 90 of whom work in Cambridge. The new location includes office and laboratory space designed to support early stage drug development and discovery.
"We are very pleased to join and contribute to the thriving life sciences community in Massachusetts," Chris Garabedian, president and CEO of Sarepta Therapeutics, said. "Operating in Cambridge provides us with access to the region's world-class biopharmaceutical talent, major academic medical centers and hospitals, and industry leaders in the RNA and rare disease fields. This access to talent and resources is critical as we develop our lead drug candidate, eteplirsen, for the treatment of DMD."
Sarepta Therapeutics recently announced another agreement to acquire a 60,000-square foot facility on 26 acres of land in Andover, Mass. The company also runs an operational facility in Corvallis, Ore., that focuses on manufacturing, research and other support functions.